Given the widespread finding that YTHDF1 is upregulated and acts as a prognostic biomarker in lung adenocarcinoma progression, targeting the YTHDF1–m6A–FTH axis could be a promising therapeutic strategy for inhibition of lung cancer occurrence and development. This evidence concerns the gene YTHDF1 and lung cancer.